Instituto de Investigación Hospital Universitario La Paz

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Dose-finding for Dobutamine During Transitional Circulation in Very Preterm Infants

Phase 1

Recruiting

Conditions: Infant, Premature, Diseases
Circulatory and Respiratory Physiological Phenomena

Interventions: Drug: Intravenous dobutamine 5 mcg/kg/min
Drug: Intravenous dobutamine 7.5 mcg/kg/min
Drug: Intravenous dobutamine 10 mcg/kg/min
Drug: Intravenous dobutamine 12.5 mcg/kg/min
Drug: Intravenous dobutamine 15 mcg/kg/min

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz

Target Recruit Count: 30

Registration Number: NCT06878742

Locations: 🇪🇸
Hospital Universitario Quironsalud, Madrid, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Universitario La Paz, Madrid, Spain

Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults

Phase 1

Not yet recruiting

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Biological: Autologous CD19/CD22 CAR T cells
Biological: Allogeneic CART-NKG2D cells

First Posted Date: 2024-11-28

Last Posted Date: 2024-11-28

Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz

Target Recruit Count: 10

Registration Number: NCT06709469

Locations: 🇪🇸
Hospital Universitario La Paz, Madrid, Spain

Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus

Phase 4

Not yet recruiting

Conditions: Kidney Disease, Chronic
Transplant Recipient (Kidney)
Immunosuppression

Interventions: Drug: Tacrolimus

First Posted Date: 2024-11-22

Last Posted Date: 2024-12-03

Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz

Target Recruit Count: 160

Registration Number: NCT06701825

Locations: 🇪🇸
Hospital La Paz, Madrid, Comunidad De Madrid, Spain

A Multicentre, Randomised, Single-blind, Controlled Protocol to Evaluate the Efficacy of Early Administration of Botulinum Toxin for Primary Midline Closure in Patients With Open Abdomen.

Phase 4

Not yet recruiting

Conditions: Botulinum Toxin Type A
Clinical Trial
Abdominal Wall
Open Abdomen

Interventions: Other: CONTROL
Drug: Botulinum Toxin A

First Posted Date: 2024-08-15

Last Posted Date: 2024-08-15

Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz

Target Recruit Count: 50

Registration Number: NCT06556030

Abdominal Aortic Aneurysm Stabilization With Truncal Cells: Controlled Clinical Trial With Historical Cohorts

Phase 2

Recruiting

Conditions: Aortic Aneurysm, Abdominal

Interventions: Drug: Allogeneic adipose tissue-derived mesenchymal stem cells

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-08

Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz

Target Recruit Count: 8

Registration Number: NCT06488898

Locations: 🇪🇸
Hospital Universitario La Paz, Madrid, Spain

Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

Phase 4

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: Second-line systemic treatment
Other: Folllow-up of second-line systemic treatment already started

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-16

Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz

Target Recruit Count: 150

Registration Number: NCT06366932

Locations: 🇪🇸
Hospital La Paz, Madrid, Spain

Assessing Interest in Web/App Platforms for Early Phase Clinical Trial Recruitment

Not yet recruiting

Conditions: Assessing Interest in a Platform for Early Phase Clinical Trial Recruitment

Interventions: Other: Questionnaires

First Posted Date: 2024-03-12

Last Posted Date: 2024-03-15

Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz

Target Recruit Count: 100

Registration Number: NCT06302647

Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model (IMIDOC)

Not Applicable

Not yet recruiting

Conditions: eHealth
Arthritis, Rheumatoid
Telemedicine
Telehealth
Rheumatic Diseases
Spondylarthritis

Interventions: Device: IMIDOC

First Posted Date: 2024-02-22

Last Posted Date: 2024-02-22

Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz

Target Recruit Count: 360

Registration Number: NCT06273306

Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins

Phase 4

Not yet recruiting

Conditions: Cardiovascular Diseases
Dyslipidemias
Pharmacogenic Myopathy
Statin Adverse Reaction

Interventions: Other: Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines
Other: Standard of Care (SoC) dosing of atorvastatin
Other: Standard of Care (SoC) dosing of simvastatin
Other: Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines
Other: Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines
Other: Standard of Care (SoC) dosing of pitavastatin
Other: Standard of Care (SoC) dosing of rosuvastatin
Other: Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines
Other: Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines
Other: Standard of Care (SoC) dosing of prasavastatin
Other: Standard of Care (SoC) dosing of lovastatin
Other: Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines
Other: Standard of Care (SoC) dosing of fluvastatin
Other: Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines